NCT05716984View on ClinicalTrials.gov

rhBNP in Type 3 Pulmonary Hypertension

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

March 30, 2024

Conditions
Group 3 Pulmonary Hypertension
Interventions
DRUG

recombinant human brain natriuretic peptide

rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.

DRUG

Placebo

placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.

Trial Locations (2)

110004

Shengjing Hospital of China Medical University, Shenyang

Unknown

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou

All Listed Sponsors
lead

Shengjing Hospital

OTHER